<DOC>
	<DOCNO>NCT00167999</DOCNO>
	<brief_summary>To determine value increase use piperacillin/tazobactam empiric therapy restrict extended-spectrum cephalosporin reduce case ESBL produce Escherichia coli Klebsiella pneumoniae hematology oncology unit</brief_summary>
	<brief_title>Study Evaluating Piperacillin-Tazobactam Certain Bacteria Hematology Oncology Units</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Klebsiella Infections</mesh_term>
	<mesh_term>Escherichia coli Infections</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<criteria>Eligible patient either sex , 15 year age old Patients admit department hematology oncology Provide write informed consent Patients hypersensitivity Î²lactam antibiotic Female pregnant breastfeed Any underlying condition noninfectious disease ultimately fatal within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Bacterial Infections</keyword>
</DOC>